Biodegradable progesterone microsphere delivery system for osteoporosis therapy

Drug Development and Industrial Pharmacy

Volumn 26, Issue 1, 2000, Pages 61-70

  Yang, Qing ^a   Owusu Ababio, Godfried ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Biodegradable; Microspheres; Osteoporosis; Progesterone; Solvent evaporation

Indexed keywords

DICHLOROMETHANE; MICROSPHERE; POLYGLACTIN; POLYLACTIC ACID; POLYVINYL ALCOHOL; PROGESTERONE; PROPANOL;

ARTICLE; BIODEGRADATION; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; EMULSION; ENCAPSULATION; EVAPORATION; OSTEOPOROSIS; PARTICLE SIZE; POSTMENOPAUSE;

ANTIMICROBIAL CATIONIC PEPTIDES; BIODEGRADATION, ENVIRONMENTAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EXCIPIENTS; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; OSTEOPOROSIS; PEPTIDES; POLYMERS; POLYVINYL ALCOHOL; PROGESTERONE;

EID: 0033969801     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-100100328     Document Type: Article

References (24)

1. R. Lindsay, Osteoporosis, a Guide to Diagnosis, Prevention, and Treatment, Raven Press, New York, 1992.
2. M. Chorev, R. Dresner-Pollak, Y. Eshel, and M. Rossenblatt, Approach to discovering novel therapeutic agents for osteoporosis based on integrin receptor blockade, Biopolymers, 37, 367-375 (1995).
3. R. Lindsay, The burden of osteoporosis: cost, Am. J. Med., 98, 9S-11S 1995).
4. F. Seeman, C. Tsalamandris, S. Bass, and G. Pearce, Present and future of osteoporosis therapy, Bone, 17(2 suppl), 23S-29S (1995).
5. S. R. Cummings, J. L. Kelsey, and M. C. Nevitt, Epidemiology of osteoporosis and osteoporotic fractures, Epidemiol. Rev., 7, 178 (1985).
6. C. Roux, Estrogen replacement therapy. What we know and what we don't. Rev. Rheum. Engl. Ed., 64, 402-409 (1997).
7. J. C. Stevenson, M. P. Cust, K. F. Gangar, T. C. Hillard, B. Lees, and M. I. Whitehead, Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women, Lancet, 336, 265-269 (1990).
8. U. Bellati, E. Iammarone, P. Bavaro, and R. D. Mattaeis, Efficacy of estrogen-progestin replacement therapy after bone marrow transplantation, Minerva Ginecol., 48, 351-354 (1996).
9. D. M. Hartmann, Morbidity of osteoporosis - can estrogen use make a public health impact? Curr. Opin. Obstet. Gynecol., 9, 289-294 (1997).
10. S. Gonnelli, C. Cepollaro, C. Pondrelli, S. Martini, R. Monaco, and C. Gennari, The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis, J. Bone Miner. Res., 12, 624-631 (1997).
11. P. M. Sarrel, Hormone replacement therapy in the menopause, Int. J. Fertil. Women's Med., 42, 78-84 (1997).
12. A. Bagur, A. Wittich, G. Ghiringhelli, E. Vega, and C. Mautalen, Hormone replacement therapy increases trabecular and cortical bone density in osteoporotic women, Medicina (B. Aires), 56, 247-251 (1996).
13. R. H. Foster and J. A. Balfour, Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy, Drugs Aging, 11, 309-332 (1997).
14. K. Lippuner, W. Haenggi, M. H. Birkhaeuser, J. P. Casez, and P. Jaeger, Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone, J. Bone Miner. Res., 12, 806-812 (1997).
15. J. A. Cauley, D. G. Seeley, W. S. Browner, K. Ensrud, L. H. Kuller, R. C. Lipschutz, and S. B. Hulley, Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures, Arch. Intern. Med., 157, 2181-2187 (1997).
16. D. J. Torgerson, R. E. Thomas, M. K. Campbell, and D. M. Reid, Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality of life results, Arch. Intern. Med., 157, 2121-2125 (1997).
17. B. J. Riis, K. Thomsen, V. Storm, and C. Christiansen, The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss, Am. J. Obstet. Gynecol., 63, 759-763 (1987).
18. B. D. Lignieres, Hormone replacement therapy: clinical benefits and side effects, Maturitas, 23(suppl), S31-S36 (1996).
19. D. Somjen, Y. Weisman, and A. M. Kaye, Pretreatment with 1,25(OH)2 vitamin D or 24,25(OH)2 vitamin D increases synergistically responsiveness to sex steroids in skeletal-derived cells, J. Steroid Biochem. Mol. Biol., 55, 211-217 (1995).
20. A. R. Gennaro Remington, The Science and Practice of Pharmacy, 19th ed., Vol. 2, Mack Publishing, Easton, Pennsylvania, 1995, pp. 1087.
21. H. M. Buckler, P. K. Kalsi, J. A. Centril, and D. C. Anderson, An audit of estradiol levels and implant frequency in women undergoing subcutaneous implant therapy, Clin. Endocrinol., 42, 445-450 (1995).
22. R. A. Miller, J. M. Brady, and D. E. Cutright, Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/ PGA copolymer ratios, J. Biomed. Mater. Res., 11, 711-719 (1997).
23. M. Habib, S. Onyilofor, N. K. Ebube, and G. Owusu-Ababio, Preparation and characterization of ofloxacin microspheres for the eradication of bone associated bacterial biofilm, J. Microencapsulation, 16, 27-37 (1999).
24. R. Jalil and J. R. Nixon, Microencapsulation using poly(DL-lactic acid) II: effect of polymer molecular weight on the microcapsule properties, J. Microencapsulation, 7, 245-254 (1990).